Clinical Trials /

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

NCT02393157

Description:

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).

Related Conditions:
  • B-Cell Lymphoblastic Lymphoma
  • Burkitt Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Grade 3 Follicular Lymphoma
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • Primary Mediastinal B-Cell Lymphoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
  • Official Title: Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL

Clinical Trial IDs

  • ORG STUDY ID: L-11,392
  • NCT ID: NCT02393157

Conditions

  • Non-Hodgkin Lymphoma
  • Burkitt Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Primary Mediastinal B-cell Lymphoma
  • CD20+ Lymphoblastic Lymphoma
  • Follicular Lymphoma, Grade III

Interventions

DrugSynonymsArms
ObinutuzumabGazyvaCNS Positive
Liposomal ARA-CDepocyteCNS Positive
IfosfamideIfexCNS Positive
CarboplatinParaplatinCNS Positive
EtoposideVP-16CNS Positive

Purpose

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).

Trial Arms

NameTypeDescriptionInterventions
Central Nervous System (CNS) NegativeExperimentalAll patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine. Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
  • Obinutuzumab
  • Liposomal ARA-C
  • Ifosfamide
  • Carboplatin
  • Etoposide
CNS PositiveExperimentalAll patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy. Liposomal cytarabine will be given intrathecally on days -13 and -5. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine. Dexamethasone will be given days -14 to -10 and days -6 through -2. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
  • Obinutuzumab
  • Liposomal ARA-C
  • Ifosfamide
  • Carboplatin
  • Etoposide

Eligibility Criteria

        Inclusion Criteria:

          -  Patients in first relapse or primary induction failure CD20 positive B-cell
             leukemia/lymphoma including:

               -  Diffuse Large B-Cell Lymphoma

               -  Burkitt Lymphoma

               -  High Grade B-cell Lymphoma: Not Otherwise Specified (NOS)

               -  Primary mediastinal B-cell lymphoma (PMBL)

               -  CD20+ B-lymphoblastic lymphoma

               -  Follicular lymphoma, Grade III

               -  Karnofsky ≥ 60% for patients > 16 years of age and

               -  Lansky ≥ 60 for patients ≤ 16 years of age.

               -  Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry
                  onto this study.

               -  Patients may not have received prior therapy with obinutuzumab (GA101)

               -  Radiation Therapy (XRT): Date of receiving prior XRT must be > 2 weeks for local
                  palliative XRT (small port); > 6 months must have elapsed if prior craniospinal
                  XRT or if > 50% radiation of pelvis; > 6 weeks must have elapsed if other
                  substantial bone marrow radiation.

               -  Steroids: Patients may have received prior steroid treatment, but not started
                  greater than 7 days prior to initiation of protocol therapy.

               -  Adequate organ function.

        Exclusion Criteria:

          -  Patients with newly diagnosed, previously untreated B-NHL.

          -  Known congenital or acquired immune deficiency.

          -  Prior solid organ transplantation.

          -  Prior allogeneic stem cell transplant within 60 days or active acute
             Graft-vs-Host-Disease (GVHD) grade 3 or higher.

          -  History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies

          -  Uncontrolled hepatitis B and/or C infection
      
Maximum Eligible Age:31 Years
Minimum Eligible Age:3 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Safety as assessed by adverse reactions and events
Time Frame:1 month
Safety Issue:
Description:Patients will be monitored for adverse reactions and events of drug when given alone and in combination with ICE chemotherapy.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:New York Medical College

Last Updated

March 11, 2019